Allergic Conjunctivitis (AC) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Allergic Conjunctivitis (AC) Marketed and Pipeline Drugs Report Overview
Allergic conjunctivitis (AC) is an inflammatory response of the conjunctiva to an allergen or irritant such as pollen, dust, and mold. It is part of a larger systemic atopic reaction and is usually seasonal, with associated upper respiratory tract symptoms and complaints of redness and swelling of the conjunctiva, with severe itching and increased lacrimation. It has been estimated that that the highest diagnosed prevalence of AC will be in China, India, and the US by 2028.
The AC marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, and late-to-mid-stage pipeline products with Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) for allergic conjunctivitis (AC). The report also analyzes the clinical and commercial landscapes of AC, as well as an assessment of deals, future market catalysts, key market players, and the future competitive environment.
Leading Marketed Drugs in AC
A few of the leading marketed drugs in Allergic Conjunctivitis are carbinoxamine maleate ER, dexamethasone SR, and grass pollen allergen extract among others.
The innovator-marketed drugs space for AC is mostly made up of dual-acting antihistamines and mast cell inhibitors (epinastine hydrochloride, ketotifen fumarate, and olopatadine hydrochloride). Topical dual-activity agents are currently considered first-line treatment in AC because of the synergetic benefit offered by these drugs. Allergen extracts are immunotherapy drugs that provide long-lasting benefits after an adequate course is completed.
Top Sponsors in the AC Marketed and Pipeline Drugs Market
A few of the top sponsors in the AC marketed and pipeline drugs market are Aldeyra Therapeutics Inc, Santen Pharmaceutical Co Ltd, NicOx SA, Ajanta Pharma Ltd, Alcon Inc, Atoll, Ora Inc, Micro Labs Inc, Faes Pharma SA, and Carisma Therapeutics Inc. Among the key players, Santen Pharmaceutical has been sponsoring the highest number of Phase III trials.
AC Marketed and Pipeline Drugs Sponsors Analysis
Buy the full Report for More Sponsor Insights into AC Marketed and Pipeline Drugs, Download a Free Report Sample
Allergic Conjunctivitis Marketed Drugs Segmentation by Mechanism of Action
The key mechanisms of action for AC marketed drugs are receptor agonist, receptor antagonist, enzyme inhibitor, cells and cell organelle inhibitor, ion channel blocker, biological factor inhibitor, cells and cell organelle disrupter, ligand inhibitor, and enzyme activator. The mechanism of action for most marketed drugs for AC is receptor agonist.
Allergic Conjunctivitis Marketed Drugs Analysis by MoA
Buy the full Report for More MoA Insights into AC Marketed Drugs, Download a Free Report Sample
AC Marketed Drugs Segmentation by Routes of Administration
The key routes of administration for AC marketed drugs are oral, topical, injection, inhalation, and suppository. Most marketed drugs for AC are oral therapies, followed by topicals.
Allergic Conjunctivitis Marketed Drugs Analysis by RoA
Buy the full Report for More RoA Insights into AC Marketed Drugs, Download a Free Report Sample
AC Marketed Drugs Segmentation by Molecule Type
The key molecule types in the AC marketed drugs are small molecule and biologic. Most marketed drugs for AC are small molecules.
Allergic Conjunctivitis Marketed Drugs Analysis by Molecule Type
Buy the full Report for More Molecule Type Insights into AC Marketed Drugs, Download a Free Report Sample
Allergic Conjunctivitis Pipeline Drugs Segmentation by Mechanisms of Action
The key mechanisms of action for AC pipeline drugs are receptor antagonist, enzyme inhibitor, biological factor inhibitor, ion channel blocker, cytotoxic to cell, ion channel activator, ligand inhibitor, protein and peptide inhibitor, and receptor agonist. Most of the AC pipeline drugs are receptor antagonists.
Allergic Conjunctivitis Pipeline Drugs Analysis by MoA
Buy the full Report for More MoA Insights into AC Pipeline Drugs, Download a Free Report Sample
AC Pipeline Drugs Segmentation by Routes of Administration
The key routes of administration for AC pipeline drugs are topical, oral, injection, inhalation, and suppository. The pipeline drugs for AC are mostly topical therapies, followed by oral.
Allergic Conjunctivitis Pipeline Drugs Analysis by RoA
Buy the full Report for More RoA Insights into AC Pipeline Drugs, Download a Free Report Sample
Allergic Conjunctivitis Pipeline Drugs Segmentation by Molecule Type
Most of the pipeline drugs for AC are small molecules. Biologic and oligonucleotide are the other significant molecule type in the pipeline drugs for AC.
Allergic Conjunctivitis Pipeline Drugs Analysis by Molecule Types
Buy the full Report for More Molecule Type Insights into AC Pipeline Drugs, Download a Free Report Sample
AC Marketed and Pipeline Drugs – Deals Landscape
- On 7th Nov 2022, Viatris Acquires Oyster Point Pharma for USD415 Million
- On 5th May 2021, Laboratorios Grin Enters into Licensing Agreement with Nicox.
Buy the full Report for More Deal Insights into AC Marketed and Pipeline Drugs, Download a Free Report Sample
| Key Mechanisms of Action (Marketed) | · Receptor Agonist
· Receptor Antagonist · Enzyme Inhibitor · Cells and Cell Organelle Inhibitor · Ion Channel Blocker |
| Key Molecule Types (Marketed) | · Small Molecule
· Biologic |
| Key Routes of Administration (Marketed) | · Oral
· Topical · Injection · Inhalation · Suppository |
| Key Mechanisms of Action (Pipeline) | · Receptor Antagonist
· Receptor Agonist · Enzyme Inhibitor · Cytotoxic to Cell · Transporter Activator |
| Key Routes of Administration (Pipeline | · Topical
· Oral · Injection · Inhalation · Suppository |
| Key Molecule Types (Pipeline) | · Small Molecule
· Biologic · Oligonucleotide |
| Top Sponsors (Marketed and Pipeline Drugs) | · Aldeyra Therapeutics Inc
· Santen Pharmaceutical Co Ltd · NicOx SA · Ajanta Pharma Ltd · Alcon Inc |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Segments Covered in the Report
AC Marketed Drugs Mechanisms of Action Outlook (Number of Drugs)
- Receptor Agonist
- Receptor Antagonist
- Enzyme Inhibitor
- Cells and Cell Organelle Inhibitor
- Ion Channel Blocker
- Biological Factor Inhibitor
- Cells and Cell Organelle Disrupter
- Ligand Inhibitor
- Enzyme Activator
AC Marketed Drugs Routes of Administration Outlook (Number of Drugs)
- Oral
- Topical
- Injection
- Inhalation
- Suppository
AC Marketed Drugs Molecule Type Outlook (Number of Drugs)
- Small Molecule
- Biologic
AC Pipeline Drugs Mechanisms of Action Outlook (Number of Drugs)
- Receptor Antagonist
- Receptor Agonist
- Enzyme Inhibitor
- Cytotoxic to Cell
- Transporter Activator
AC Pipeline Drugs Routes of Administration Outlook (Number of Drugs)
- Topical
- Oral
- Injection
- Inhalation
- Suppository
AC Pipeline Drugs Molecule Types Outlook (Number of Drugs)
- Small Molecule
- Biologic
- Oligonucleotide
Scope
GlobalData’s Allergic Conjunctivitis (AC) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the AC market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AC market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
What are the key mechanisms of action for AC marketed drugs?
The key mechanisms of action for AC marketed drugs are receptor agonist, receptor antagonist, enzyme inhibitor, cells and cell organelle inhibitor, ion channel blocker, biological factor inhibitor, cells and cell organelle disrupter, ligand inhibitor, and enzyme activator.
-
What are the key routes of administration for AC marketed drugs?
The key routes of administration for AC marketed drugs are oral, topical, injection, inhalation, and suppository.
-
What are the key mechanisms of action for AC pipeline drugs?
The key mechanisms of action for AC pipeline drugs are receptor antagonist, enzyme inhibitor, biological factor inhibitor, ion channel blocker, cytotoxic to cell, ion channel activator, ligand inhibitor, protein and peptide inhibitor, and receptor agonist.
-
What are the key routes of administration for AC pipeline drugs?
The key routes of administration for AC pipeline drugs are topical, oral, injection, inhalation and suppository.
-
What are the key molecule types for AC pipeline drugs?
The key molecule types in the AC pipeline drugs market are small molecule, biologic, and oligonucleotide.
-
Who are the top sponsors for AC marketed and pipeline drugs market?
A few of the top sponsors in the AC marketed and pipeline drugs market are Aldeyra Therapeutics Inc, Santen Pharmaceutical Co Ltd, NicOx SA, Ajanta Pharma Ltd, Alcon Inc, Atoll, Ora Inc, Micro Labs Inc, Faes Pharma SA, and Carisma Therapeutics Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Sample Report
Allergic Conjunctivitis (AC) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Allergic Conjunctivitis reports